Observational studyBritish journal of clinical pharmacology2017
Individualising the dose of allopurinol in patients with gout.
Observational study in British journal of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Non-genetic Risk Factors for Allopurinol-Induced Severe Cutaneous Adverse Reaction (SCAR): A Systematic Review.Drug safety · 2026Pooled it
- Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.Clinical and translational science · 2021Trial
- Hepatic Safety of Febuxostat and Allopurinol in Gout Patients: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.Therapeutics and clinical risk management · 2025Review
- Development and validation of a prediction nomogram for depressive symptoms in gout patients.Frontiers in public health · 2024Article
- Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.British journal of clinical pharmacology · 2023Article
- Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial.Therapeutics and clinical risk management · 2023Review
- Honorary Professor Garry Graham.Inflammopharmacology · 2021Article
- Better outcomes for patients with gout.Inflammopharmacology · 2020Article
- Should our approach to diuretic using in patients with gout change?Arthritis research & therapy · 2018Article
- Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.Current rheumatology reports · 2018Review
- Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy.Arthritis research & therapy · 2018Article
- Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort.Arthritis research & therapy · 2018Article
- Individualising the dose of allopurinol in patients with gout.British journal of clinical pharmacology · 2017Observational
- Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.Drug design, development and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aims of the study were to: 1) determine if a plasma oxypurinol concentration-response relationship or an allopurinol dose-response relationship best predicts the dose requirements of allopurinol in the treatment of gout; and 2) to construct a nomogram for calculating the optimum maintenance dose of allopurinol to achieve target serum urate (SU) concentrations.
methodsA nonlinear regression analysis was used to examine the plasma oxypurinol concentration- and allopurinol dose-response relationships with serum urate. In 81 patients (205 samples), creatinine clearance (CL
resultsThe final plasma oxypurinol concentration-response relationship (U
conclusionsPlasma oxypurinol concentrations, CL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.